Clinical Trial

Efficacy, Safety and Neural Mechanism of Stellate Ganglion Block in the Treatment of Anxiety. Disorder.

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2024 (before its estimated July 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
1. In this study, ultrasound-guided Stellate Ganglion Block(SGB) will be used in the treatment of anxiety disorders, combined with relevant scales, HRV indicators and resting state functional magnetic resonance data, to explore the safety and effectiveness of SGB in the treatment of anxiety disorders, and to explore whether its mechanism of action is related to the excitability of sympathetic nervous system and the activity changes of insular cortex. 2. Verify the following hypothesis: (1) SGB is a safe, well-tolerated and acceptable treatment technique; (2) After SGB treatment, the anxiety symptoms of the patients were relieved to a certain extent and the psychological function was restored; (3) The sympathetic excitability of patients after SGB treatment is reduced, and this effect can be monitored by heart rate variability; (4) The activity of insular cortex decreased after SGB treatment.
Trial Details
NCT Number NCT06540313
Lead Sponsor Nanjing Medical University
Conditions Anxiety Disorders, Stellate Ganglion Block
Enrollment 60 participants
Start Date 2024-09-01
Primary Completion 2025-07-10 (estimated)
Study Completion 2026-06-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-06